Breadcrumb

[A19-55] Dolutegravir/lamivudine (HIV infection) - Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2019-07-04 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 504 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A19-103] Dolutegravir/lamivudine (HIV infection) - Second Addendum to Commission A19-55
Status: Commission completed

[A19-102] Dolutegravir/lamivudine (HIV infection) - Addendum to Commission A19-55
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2019-11-04 Extract of dossier assessment 504 kBPDFdownload file
2019-11-04 Dossier assessment (German version) 835 kBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Extract of dossier assessment

  File-Icon  Dolutegravir/lamivudine (HIV infection) - Benefit assessment according to §35a Social Code Book V [PDF, 504 kB]

Federal Joint Committee (G-BA)

2020-02-06 A G-BA decision was published.

G-BA documents on this decision



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close